Abstract: A process for selective formation of ethanol from acetic acid by hydrogenating acetic acid in the presence of a catalyst comprising a modified support having cobalt and an alkaline earth support modifier. The active metals may include a first metal of palladium, platinum, and combinations thereof and a second metal of copper, iron, nickel, zinc, silver, chromium, tin, and combinations thereof.

Abstract: This invention relates to veterinary compositions for treating and/or preventing fleas or ticks infection or infestation in an animal comprising an isoxazoline active agent of Formula (II): or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Abstract: We describe a method of determining whether a cancer cell is likely to be resistant to treatment by an mTOR inhibitor. The method may comprise detecting PPP2R2B (GenBank Accession Number: NM_18167) in or of the cell. It may, alternatively, or in addition, comprise detecting PDK1 (GenBank Accession Number: NM_002613), in or of the cell. The method may comprise detecting methylation of the PPP2R2B promoter in or of the cell. It may comprise detecting the expression and/or activity of PPP2R2B in or of the cell. It may comprise detecting PDK1 mediated Myc phosphorylation activity.

Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.

Abstract: Antibodies to human ?V-tubulin, fragments thereof, and compositions comprising such are provided. Diagnostic, prognostic and identification methods employing such antibodies or fragments thereof are also provided.

Abstract: The present disclosure relates generally to water concentration reduction processes within an adipic acid process. The present invention also includes process for converting a glucose-containing feed derived from a carbohydrate source to an adipic acid product wherein the process includes the steps of: converting glucose in the feed to a reaction product including a hydrodeoxygenation substrate and a first concentration of water; reducing the concentration of water in the reaction product to produce a feedstock including the hydrodeoxygenation substrate and second concentration of water, wherein the second concentration of water is less than the first concentration of water; and converting at least a portion of the hydrodeoxygenation substrate in the feedstock to an adipic acid product. Processes are also disclosed for producing hexamethylene diamine and caprolactam from the adipic acid product.

Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:

Abstract: Process for the preparation of catalytic support and supported bimetallic catalysts for production of homopolymers and copolymers of ethylene with ?-olefins, of high and ultra high molecular weight and with broad molecular weight distribution in slurry, bulk and gas phase processes and products thereof. The present invention relates to a process for the preparation of catalytic support and the supported bimetallic catalysts, used in the production of ethylene homopolymers and ethylene copolymers with ?-olefins, of high and ultra high molecular weight with broad molecular weight distribution, in gas or liquid phase polymerization processes, the latter being in slurry, bulk or suspension, and the products obtained from these processes.

Abstract: A method of treating pain involves administering to a human in need of such treatment a therapeutically effective amount of hyaluronic acid. In some embodiments, the hyaluronic acid is a non-avian based non-cross linked hyaluronic acid configured to treat post-traumatic and degenerative joint disorders. In some embodiments, the hyaluronic acid is cross linked hyaluronic acid.

Abstract: Disclosed herein are substituted fluoromethanes; pharmaceutical compositions comprising a therapeutically effective amount of the same; processes for preparing these fluoromethanes; and methods of using the same in alleviating infection and parasitism. Also disclosed are methods for identifying substituted fluoromethanes for modulating the activity of receptors and enzymes that bind and/or modify phosphate containing ligands and substrates.

Abstract: The present disclosure is directed to compositions and methods for detecting elevated microRNA U6 concentrations in serum relative to a standard microRNA (e.g. SNORD44) as a diagnostic indicator of metastatic disease. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual.

Abstract: An augmented ceramic composite including aluminosilicate nanotubes may be added to a biocompatible polymer matrix. Aluminosilicate nanotubes have a surprisingly high biocompatibility, radio opaqueness, and suitability for storing therapeutic compounds for release over time. These surprising advantages make aluminosilicate nanotubes, such as halloysite nanotubes, a good candidate for use in various medical applications from bone and dental prosthetics to cancer treatment and prevention. Furthermore, unlike other additives, the addition of certain quantities of halloysite nanotubes increases the strength of the polymer matrix to which it is added.

Abstract: The present invention relates in general to the field of targeted drug delivery of anti-cancer drugs. More precisely, the present invention concerns polymer drug conjugates, namely, conjugates of poly(organo)phosphazenes and anti-cancer drugs, wherein the conjugates are suitable to selectively release anti-cancer drugs in tumor tissue. In addition, the present invention relates to a method for manufacturing such poly(organo)phosphazene molecule conjugates, to poly(organo)phosphazene molecule conjugates for use in medicine, in particular, to poly(organo)phosphazene molecule conjugates for use in the treatment of cancer, and to pharmaceutical compositions comprising such poly(organo)phosphazene molecule conjugates.

Abstract: This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

Abstract: A primary object of the present invention is to provide a polylactic acid decomposition method that efficiently decomposes polylactic acid so that the polylactic acid can readily undergo degradation by a biological treatment such as methane fermentation. Specifically, the present invention provides a polylactic acid decomposition method involving a step of impregnating a polylactic acid-containing organic material with a treatment solution containing an organic acid salt and/or inorganic acid salt of an amine compound.

Abstract: Methods and catalyst compositions for formation of furans from carbohydrates. A carbohydrate substrate is heating in the presence of a 2-substituted phenylboronic acid (or salt or hydrate thereof) and optionally a magnesium or calcium halide salt. The reaction is carried out in a polar aprotic solvent other than an ionic liquid, an ionic liquid or a mixture thereof. Additional of a selected amount of water to the reaction can enhance the yield of furans.

Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Abstract: The present invention relates to reduced toxicity of functional alcoholic beverage composition comprising distilled alcohol, deionized water, 18?-Glycyrrhizin or 18?-Glycyrrhizin and a sugar alcohol or sugars, having pH in the range of 4.0-9.0. More particularly, alcoholic beverage composition comprises distilled alcohol, deionized water, 18?-Glycyrrhizin or 18?-Glycyrrhizin and a sugar alcohol/sugars as hepato-protectants. The present invention provides an alcoholic beverage for reducing hepatotoxicity caused by its consumption and a process to manufacture the said alcoholic beverage.

Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).

Abstract: This specification discloses an operational continuous process to convert lignin as found in ligno-cellulosic biomass before or after converting at least some of the carbohydrates. The continuous process has been demonstrated to create a slurry comprised of lignin, raise the slurry comprised of lignin to ultra-high pressure, deoxygenate the lignin in a lignin conversion reactor over a catalyst which is not a fixed bed without producing char. The conversion products of the carbohydrates or lignin can be further processed into polyester intermediates for use in polyester preforms and bottles.